An Outbreak of Escherichia coli O157:H7 Infection from Unpasteurized Commercial Apple Juice

  1. Sara H. Cody, MD;
  2. M. Kathleen Glynn, DVM, MPVM;
  3. Jeff A. Farrar, DVM, MPH, PhD;
  4. K. Lisa Cairns, MD, MPH;
  5. Patricia M. Griffin, MD;
  6. John Kobayashi, MD;
  7. Murray Fyfe, MD, MSc, FRCPC;
  8. Richard Hoffman, MD, MPH;
  9. Arlene S. King, MD, FRCPC;
  10. Jay H. Lewis, BS;
  11. Balasubr Swaminathan, PhD;
  12. Raymond G. Bryant, BA; and
  13. Duc J. Vugia, MD, MPH
  1. From California Department of Health Services, Berkeley, Sacramento, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Washington State Department of Health, Shoreline, Washington; British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada; Laboratory Centre for Disease Control, Health Canada, Ottawa, Ontario, Canada; and Colorado Department of Public Health and Environment, Denver, Colorado.

    Abstract

    Background: Escherichia coli O157:H7 infections have traditionally been associated with animal products, but outbreaks associated with produce have been reported with increasing frequency. In fall 1996, a small cluster of E. coli O157:H7 infections was epidemiologically linked to a particular brand (brand A) of unpasteurized apple juice.

    Objective: To define the extent of the outbreak, confirm the source, and determine how the apple juice became contaminated.

    Design: Descriptive epidemiologic study and traceback investigation.

    Setting: Western United States and British Columbia, Canada.

    Patients: Patients with E. coli O157:H7 infection who were exposed to brand A apple juice.

    Measurements: Clinical outcome and juice exposure histories of case-patients, pulsed-field gel electrophoresis of case and juice isolates, and juice production practices.

    Results: Seventy persons with E. coli O157:H7 infection and exposure to brand A unpasteurized apple juice were identified. Of these persons, 25 (36%) were hospitalized, 14 (20%) developed the hemolytic uremic syndrome, and 1 (1%) died. Recalled apple juice that was produced on 7 October 1996 grew E. coli O157:H7 with a pulsed-field gel electrophoresis pattern indistinguishable from that of case isolates. Apple juice produced on 7 October 1996 accounted for almost all of the cases, and the source of contamination was suspected to be incoming apples. Three lots of apples could explain contamination of the juice: Two lots originated from an orchard frequented by deer that were subsequently shown to carry E. coli O157:H7, and one lot contained decayed apples that had been waxed.

    Conclusions: Standard procedures at a state-of-the-art plant that produced unpasteurized juices were inadequate to eliminate contamination with E. coli O157:H7. This outbreak demonstrated that unpasteurized juices must be considered a potentially hazardous food and led to widespread changes in the fresh juice industry.

    Article and Author Information

    • Acknowledgments: The authors thank E. Russell Alexander and Janice Boase (Seattle-King County Department of Public Health) for providing the results of their case–control study and for initiating the investigation that followed; Mansour Samadpour (University of Washington) for rapid subtyping of specimens, which allowed early detection of the outbreak; Helen Hamoaka (Fresno District Office of the Food and Drug Administration) for leading the plant investigation; Andrew Bound (Food and Drug Administration Laboratory, Seattle) for isolation of the E. coli O157:H7 organism from a juice sample; William Bibb, Peggy Hayes, and Nancy Strockbine (Centers for Disease Control and Prevention) for performing the serologic, subtyping, and PCR studies, respectively; Sharon Abbott, Greg Inami, and Janet Mohle-Botani (California Department of Health Services) for subtyping of clinical specimens, testing of environmental samples, and case findings, respectively; Pamela Shillam (Colorado Department of Public Health and Environment) for case investigation; and Lyn Dupré, Douglas Owens, and Andrew Pelletier for comments on the manuscript.

    • Requests for Reprints: Sara H. Cody, MD, Disease Prevention and Control, Santa Clara County Department of Public Health, 2220 Moorpark Avenue, #115, San Jose, CA 95128.

    • Current Author Addresses: Dr. Cody: Disease Prevention and Control, Santa Clara County Department of Public Health, 2220 Moorpark Avenue, #115, San Jose, CA 95128.

    • Dr. Glynn: Division of Public Health Surveillance and Informatics, Epidemiology Program Office, Centers for Disease Control and Prevention, 1600 Clifton Road, Mail Stop C-08, Atlanta, GA 30333.

    • Dr. Farrar: Food and Drug Branch, California Department of Health Services, 601 North 7th Street, Sacramento, CA 94234.

    • Dr. Cairns: Epidemiology Program Office, Centers for Disease Control and Prevention, 1600 Clifton Road, Mail Stop D-18, Atlanta, GA 30333.

    • Drs. Griffin and Swaminathan: Foodborne and Diarrheal Diseases Branch, Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Mail Stop A-38, Atlanta, GA 30333.

    • Dr. Kobayashi and Mr. Lewis: Washington State Department of Health, 1610 Northeast 150th Street, Shoreline, WA 98155.

    • Drs. Fyfe and King: British Columbia Centre for Disease Control, 655 West 12th Avenue, Vancouver, British Columbia V52Z 4R4, Canada.

    • Dr. Hoffman: Colorado Department of Public Health and Environment, 4300 Cherry Creek Drive, Denver, CO 80246.

    • Mr. Bryant: Microbial Diseases Laboratory, California Department of Health Services, 2151 Berkeley Way, Berkeley, CA 94704.

    • Dr. Vugia: Division of Communicable Disease Control, California Department of Health Services, 2151 Berkeley Way, Berkeley, CA 94704.

    | Table of Contents
    Most Read Most Read
    Most Commented Most Commented On
    Annals in the News Annals in the News
    Clinical Trials Clinical Trials
    Comparative Effectiveness Comparative Effectiveness
    Hospital Medicine Hospital Medicine
    • Advertisement
    • Advertisement